# Windward Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/windward-bio

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.windwardbio.com/
- Total disclosed funding: $365M
- Latest round: Series B (May 4, 2026)
- Investors on record: 13

## About

Based in Basel, Switzerland, Windward Bio AG specializes in creating therapeutic solutions for severe immunological conditions. The company was founded by its CEO, Luca Santarelli. In May 2026, Windward Bio AG raised USD 165 million in venture funding led by returning investor OrbiMed Advisors, with participation from other returning investors Pivotal Life Sciences, Qiming Venture Partners, Quan Capital, RTW Investments, Blue Owl, SR One, Novo Holdings, and Omega Funds. New investors RA Capital Management, Sanofi Ventures, Harbour BioMed, Janus Henderson Investors and other unspecified investors also participated in the round.

Windward Bio focuses on the development of advanced therapeutic solutions aimed at improving outcomes for individuals with severe immunological diseases, particularly severe respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company's primary product is WIN378, a novel recombinant fully human monoclonal antibody designed to selectively bind to the thymic stromal lymphopoietin (TSLP) ligand, a cytokine linked to a range of inflammatory diseases. By inhibiting the TSLP ligand, WIN378 aims to reduce the inflammatory responses associated with these conditions, thereby potentially offering benefits to patients. Additionally, the firm is developing long-acting bispecific antibody programs tailored to treat various immunological disorders.

The company generates revenue through partnerships with healthcare providers and pharmaceutical companies, potentially employing a business-to-business (B2B) transaction structure.

The company plans to utilize the May 2026 funding to advance its clinical programs, including moving its lead drug into late-stage trials and supporting studies for additional treatments.

## Funding rounds

- Series B, May 4, 2026, $165M — OrbiMed Advisors, SR One, Novo Holdings, Qiming Venture Partners, Omega Funds, Sanofi Ventures, RTW Investments, RA Capital Management, Janus Henderson Investors, Harbour BioMed, Pivotal Life Sciences, Quan Capital, Blue Owl
- Series A, Jan 10, 2025, $200M — OrbiMed Advisors, SR One, Novo Holdings, Qiming Venture Partners, Omega Funds, RTW Investments, Pivotal Life Sciences, Quan Capital, Blue Owl

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B
- Novo Holdings — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A, Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series A, Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series A, Series B
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series A, Series B
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series A, Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Janus Henderson Investors — Series B
- Harbour BioMed — Series B